Asked by: Tim Loughton (Conservative - East Worthing and Shoreham)
Question to the Department for Business and Trade:
To ask the Secretary of State for Business and Trade, whether provisions have been made for employees of The Bodyshop who were made redundant.
Answered by Kevin Hollinrake - Minister of State (Department for Business and Trade)
I understand this will be a concerning time for those impacted. The Department for Work and Pensions’ Rapid Response Service is a service designed to give support and advice to employers and their employees when faced with redundancy.
The range of support may include:
Employees may be entitled to statutory redundancy pay, compensatory notice pay and holiday pay from the Insolvency Service. Further information may be found at https://www.gov.uk/government/news/the-body-shop-in-administration-information-for-employees-and-creditors.
Asked by: Layla Moran (Liberal Democrat - Oxford West and Abingdon)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what assessment she has made of the adequacy of the availability of NHS provision for the diagnosis of ADHD in (a) Oxfordshire and (b) England.
Answered by Maria Caulfield - Parliamentary Under Secretary of State (Department for Business and Trade) (Minister for Women)
It is the responsibility of integrated care boards (ICBs) to make available appropriate provision to meet the health and care needs of their local population, including access to attention deficit hyperactivity disorder (ADHD) assessment and treatment, in line with relevant National Institute for Health and Care Excellence (NICE) guidance. The NICE guideline on ADHD does not recommend a maximum waiting time from referral for an assessment of ADHD to the point of assessment or diagnosis. The Department has not made a specific assessment of the availability of National Health Service provision for the diagnosis of, or treatment of, ADHD in Oxfordshire.
In respect of the adequacy of ADHD service provision nationally, in December 2023, NHS England initiated a rapid piece of work to consider ADHD service provision within the NHS. The initial phase of work identified challenges, including with current service models and the ability to keep pace with demand. Following this initial review, NHS England is establishing a new ADHD taskforce alongside the Government, to look at ADHD service provision and its impact on patient experience. The new taskforce will bring together expertise from across a broad range of sectors, including the NHS, education, and justice, to better understand the challenges affecting people with ADHD, and to help provide a joined up approach in response to concerns around rising demand.
Alongside the work of the taskforce, NHS England has announced that it will continue to work with stakeholders to develop a national ADHD data improvement plan, carry out more detailed work to understand the provider and commissioning landscape, and capture examples from local health systems which are trialling innovative ways of delivering ADHD services, to ensure best practice is captured and shared across the system.
In respect of the availability of NHS provision for the treatment of ADHD nationally, the Department is aware of, and taking action to address, disruptions to the supply of medicine used for the management of ADHD. Disruptions to the supply of medicines have been primarily driven by issues which have resulted in capacity constraints at key manufacturing sites. Nationally, the Department has been working hard with industry to help resolve those issues as quickly as possible. As a result of our ongoing activity, some issues have been resolved. However, we know that there continue to be disruptions to the supply of some other medicines, including methylphenidate and guanfacine. The latest information we have received from manufacturers is that these should largely be resolved by May 2024 and October 2024, respectively.
Asked by: Layla Moran (Liberal Democrat - Oxford West and Abingdon)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what assessment she has made of the adequacy of the availability of NHS provision for the treatment of ADHD in (a) Oxfordshire and (b) England.
Answered by Maria Caulfield - Parliamentary Under Secretary of State (Department for Business and Trade) (Minister for Women)
It is the responsibility of integrated care boards (ICBs) to make available appropriate provision to meet the health and care needs of their local population, including access to attention deficit hyperactivity disorder (ADHD) assessment and treatment, in line with relevant National Institute for Health and Care Excellence (NICE) guidance. The NICE guideline on ADHD does not recommend a maximum waiting time from referral for an assessment of ADHD to the point of assessment or diagnosis. The Department has not made a specific assessment of the availability of National Health Service provision for the diagnosis of, or treatment of, ADHD in Oxfordshire.
In respect of the adequacy of ADHD service provision nationally, in December 2023, NHS England initiated a rapid piece of work to consider ADHD service provision within the NHS. The initial phase of work identified challenges, including with current service models and the ability to keep pace with demand. Following this initial review, NHS England is establishing a new ADHD taskforce alongside the Government, to look at ADHD service provision and its impact on patient experience. The new taskforce will bring together expertise from across a broad range of sectors, including the NHS, education, and justice, to better understand the challenges affecting people with ADHD, and to help provide a joined up approach in response to concerns around rising demand.
Alongside the work of the taskforce, NHS England has announced that it will continue to work with stakeholders to develop a national ADHD data improvement plan, carry out more detailed work to understand the provider and commissioning landscape, and capture examples from local health systems which are trialling innovative ways of delivering ADHD services, to ensure best practice is captured and shared across the system.
In respect of the availability of NHS provision for the treatment of ADHD nationally, the Department is aware of, and taking action to address, disruptions to the supply of medicine used for the management of ADHD. Disruptions to the supply of medicines have been primarily driven by issues which have resulted in capacity constraints at key manufacturing sites. Nationally, the Department has been working hard with industry to help resolve those issues as quickly as possible. As a result of our ongoing activity, some issues have been resolved. However, we know that there continue to be disruptions to the supply of some other medicines, including methylphenidate and guanfacine. The latest information we have received from manufacturers is that these should largely be resolved by May 2024 and October 2024, respectively.
Asked by: Stephen Morgan (Labour - Portsmouth South)
Question to the Department for Business and Trade:
To ask the Secretary of State for Business and Trade, whether her Department is taking steps to help support people made redundant by The Body Shop International Limited.
Answered by Kevin Hollinrake - Minister of State (Department for Business and Trade)
While this is a commercial decision for the company, we understand that this will be a concerning time for workers at The Body Shop, and we stand ready to support those impacted.
Affected employees will be able to access our broad range of support, including Universal Credit and JobCentre Plus, through the Department for Work and Pension's Rapid Response Service.
Employees who worked for the company under an employment contract may be eligible for statutory redundancy pay, compensatory notice pay, and holiday pay, for which they can apply to the Insolvency Service.
Asked by: Lord Roberts of Llandudno (Liberal Democrat - Life peer)
Question to the Department for Work and Pensions:
To ask His Majesty's Government what plans they have to provide support to those whose livelihoods previously relied on employment at the Port Talbot steel works.
Answered by Viscount Younger of Leckie - Parliamentary Under-Secretary (Department for Work and Pensions)
The Department for Work and Pensions (DWP) stands ready to support anyone affected by redundancy with our Rapid Response Service offer. This is a service designed to give support and advice to employers and their employees when faced with redundancy.
This service is co-ordinated nationally by the National Employer and Partnership Team and is managed by Jobcentre Plus. Delivery partners include Careers Wales, local training providers, Money Helper and ReAct Plus in Wales.
The Rapid Response Service offer is flexible and can include a range of options (see below) that can be pulled together into an appropriate support package. This package will be tailored to meet the needs of the employer, the individuals affected and the local community.
The range of support available from Jobcentre Plus and partners may include:
DWP are also working closely with the Transition Board that was established to support the people, businesses and communities affected by the proposals for Tata Steel in Port Talbot.
Asked by: Simon Lightwood (Labour (Co-op) - Wakefield)
Question to the Department for Work and Pensions:
To ask the Secretary of State for Work and Pensions, how many and what proportion of claimants who were given a negative decision following the suspension of their claim by the Risk Review Team or Enhanced Review Team (a) appealed that decision and (b) had a tribunal allow their appeal in each of the last five years.
Answered by Paul Maynard - Parliamentary Under-Secretary (Department for Work and Pensions)
The Risk Review Team (RRT) has now been incorporated in to a broader and wide-ranging Enhanced Review Team (ERT), aimed at identifying and stopping fraud early.
As the NAO have reported in the Annual Report and Accounts 2022-23. ‘The majority of 2022-23 savings (£650 million) came from the Enhanced Review Team (ERT), which provides a rapid response service for detailed checking of high-risk Universal Credit claims before they go into payment. These estimates also suggest that preventative actions have a much higher level of return than investigating fraud and error after it has occurred.’
Data on how many and what proportion of cases handled by ERT have resulted in suspension is not available to this level for ERT and to produce it would incur disproportionate costs. This is due to large volumes of data being held across different clerical platforms, which would need to be forensically examined.
Likewise, data on cases closed, reinstated, or remaining suspended, cannot be provided within reasonable costs.
We are unable to provide the number of claimants who have appealed decisions on cases closed following RRT/ERT action and the number who have been successful in their appeals over the last five years because ERT only started completing reviews in April 2020.
We are unable to give per year figures since the formation of ERT due to the lengthy dispute process and are also unable to identify which appeals would have previously been suspended, due to this data not being held. However, the cumulative total of cases for RRT and ERT that have been through the dispute process are:
Asked by: Simon Lightwood (Labour (Co-op) - Wakefield)
Question to the Department for Work and Pensions:
To ask the Secretary of State for Work and Pensions, how many and what proportion of benefit claims suspended by the (a) Risk Review Team and (b) Enhanced Review Team in each of the last three years (i) have subsequently been (A) closed and (B) reinstated and (ii) remain suspended.
Answered by Paul Maynard - Parliamentary Under-Secretary (Department for Work and Pensions)
The Risk Review Team (RRT) has now been incorporated in to a broader and wide-ranging Enhanced Review Team (ERT), aimed at identifying and stopping fraud early.
As the NAO have reported in the Annual Report and Accounts 2022-23. ‘The majority of 2022-23 savings (£650 million) came from the Enhanced Review Team (ERT), which provides a rapid response service for detailed checking of high-risk Universal Credit claims before they go into payment. These estimates also suggest that preventative actions have a much higher level of return than investigating fraud and error after it has occurred.’
Data on how many and what proportion of cases handled by ERT have resulted in suspension is not available to this level for ERT and to produce it would incur disproportionate costs. This is due to large volumes of data being held across different clerical platforms, which would need to be forensically examined.
Likewise, data on cases closed, reinstated, or remaining suspended, cannot be provided within reasonable costs.
We are unable to provide the number of claimants who have appealed decisions on cases closed following RRT/ERT action and the number who have been successful in their appeals over the last five years because ERT only started completing reviews in April 2020.
We are unable to give per year figures since the formation of ERT due to the lengthy dispute process and are also unable to identify which appeals would have previously been suspended, due to this data not being held. However, the cumulative total of cases for RRT and ERT that have been through the dispute process are:
Asked by: Simon Lightwood (Labour (Co-op) - Wakefield)
Question to the Department for Work and Pensions:
To ask the Secretary of State for Work and Pensions, how many and what proportion of benefit claims (a) flagged and (b) investigated by the (i) Risk Review Team and (ii) Enhanced Review Team have resulted in the suspension of benefits in each of the last three years.
Answered by Paul Maynard - Parliamentary Under-Secretary (Department for Work and Pensions)
The Risk Review Team (RRT) has now been incorporated in to a broader and wide-ranging Enhanced Review Team (ERT), aimed at identifying and stopping fraud early.
As the NAO have reported in the Annual Report and Accounts 2022-23. ‘The majority of 2022-23 savings (£650 million) came from the Enhanced Review Team (ERT), which provides a rapid response service for detailed checking of high-risk Universal Credit claims before they go into payment. These estimates also suggest that preventative actions have a much higher level of return than investigating fraud and error after it has occurred.’
Data on how many and what proportion of cases handled by ERT have resulted in suspension is not available to this level for ERT and to produce it would incur disproportionate costs. This is due to large volumes of data being held across different clerical platforms, which would need to be forensically examined.
Likewise, data on cases closed, reinstated, or remaining suspended, cannot be provided within reasonable costs.
We are unable to provide the number of claimants who have appealed decisions on cases closed following RRT/ERT action and the number who have been successful in their appeals over the last five years because ERT only started completing reviews in April 2020.
We are unable to give per year figures since the formation of ERT due to the lengthy dispute process and are also unable to identify which appeals would have previously been suspended, due to this data not being held. However, the cumulative total of cases for RRT and ERT that have been through the dispute process are:
Asked by: Simon Lightwood (Labour (Co-op) - Wakefield)
Question to the Department for Work and Pensions:
To ask the Secretary of State for Work and Pensions, what guidance his Department provides to the (a) risk review team and (b) enhanced review team on suspension and termination.
Answered by Paul Maynard - Parliamentary Under-Secretary (Department for Work and Pensions)
All members of ERT are provided with full training and with guidance which is clear about how case suspensions and terminations (closures) should be handled.
If a suspension is put in place on a claim, the claimant is made fully aware of any actions they need to take and information they need to provide in order to progress the review of their case.
A clear explanation is also provided to the claimant about the potential consequences should they fail to fully comply with these requirements within the required timescales. The guidance also ensures that ERT team members consider potential customer vulnerability throughout the duration of any intervention.
As the NAO have reported in the Annual Report and Accounts 2022-23, ‘The majority of 2022-23 savings (£650 million) came from the Enhanced Review Team (ERT), which provides a rapid response service for detailed checking of high-risk Universal Credit claims before they go into payment. These estimates also suggest that preventative actions have a much higher level of return than investigating fraud and error after it has occurred.’
Asked by: Andrew Bridgen (Independent - North West Leicestershire)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, with reference to the guidance by NICE entitled Covid-19 rapid guideline: managing symptoms including at the end of life in the community, NG163, published on 3 April 2020, by what process (a) that guidance was commissioned and (b) the NHS decided (i) to procure Midazolam for use in (A) end-of-life and (B) other patient care and (ii) the quantity of Midazolam it would procure in each of the last four years.
Answered by Andrew Stephenson - Minister of State (Department of Health and Social Care)
The National Institute for Health and Care Excellence (NICE) guideline NG163 published in 2020 was commissioned as part of a programme to provide rapid guidance on the management of affected patients with COVID-19. Several of NICE’s COVID-19 rapid guidelines were incorporated into a single guideline for the management of COVID-19 in children and adults (NG191), which was last updated in June 2023.
Early in the pandemic, NHS England convened a National Clinical Group comprising senior specialist clinicians and relevant specialist pharmacists to develop priority medicines lists for critical care, end of life care and antibiotics and these were kept under review as the pandemic and subsequent clinical knowledge evolved. As part of this process, midazolam was identified as a priority medicine for use in both critical care as an alternative to propofol in the sedatives category, and end of life care as a first line medicine in the anxiety category.
The following table shows the quantity of midazolam procured by the National Health Service in England using NHS England procurement frameworks for use in secondary care in each of the last four years to 2023/24:
Financial year | Quantity of packs |
2020/21 | 587,003 |
2021/22 | 482,458 |
2022/23 | 415,512 |
2023/24 | 229,693 |
It is not possible to differentiate between Midazolam use in end of life and other patient care. This data excludes procurement for use in primary and community care.
In primary health care, procurement is undertaken by retail pharmacies on an individual basis, based on their perception of future demand needs or in direct response to prescriptions received from patients. There is no centralised procurement process for primary care and therefore there is no information that is relevant to the question asked.
Health is largely a devolved matter, and decisions on the procurement of medicines in Scotland, Wales and Northern Ireland are therefore a matter for the Scottish Government, Welsh Government and Northern Ireland Executive respectively.